Cancer

January 31, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm https://genomediscovery.org/wp-content/uploads/2019/01/MiR-129-fns-as-an-anticancer-agent-through-induction-of-CADM1-and-BIRC5.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/01/MiR-129-fns-as-an-anticancer-agent-through-induction-of-CADM1-and-BIRC5.jpg January 31, 2019 January 31, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

January 30, 2019

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm https://genomediscovery.org/wp-content/uploads/2019/01/A-pharmaceutical-mixture-encompassing-Probiotics-Clostridium-butyricum-MIYAIRI-588-CBM588-attenuates-tumorigenesis-through-induciton-of-BTG2-and-SMADCA4-.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/01/A-pharmaceutical-mixture-encompassing-Probiotics-Clostridium-butyricum-MIYAIRI-588-CBM588-attenuates-tumorigenesis-through-induciton-of-BTG2-and-SMADCA4-.jpg January 30, 2019 January 30, 2019

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture…

January 27, 2019

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SAV1/WW45, PP2A, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 27/January/2019, `11.47 pm

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SAV1/WW45, PP2A, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 27/January/2019, `11.47 pm https://genomediscovery.org/wp-content/uploads/2019/01/Probiotics-Clostridium-butyricum-MIYAIRI-588-CBM588-increases-SAV1-and-PP2A-expression-and-attenuates-tumor-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/01/Probiotics-Clostridium-butyricum-MIYAIRI-588-CBM588-increases-SAV1-and-PP2A-expression-and-attenuates-tumor-progression.jpg January 27, 2019 January 30, 2019

January 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Mevastatin, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1,PDCD4, p53, p21, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/January/2018, 5.33 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Mevastatin, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1,PDCD4, p53, p21, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/January/2018, 5.33 pm https://genomediscovery.org/wp-content/uploads/2019/01/A-pharmaceutical-mixture-encompassing-Mevastatin-or-the-probiotic-Lactobacillus-attenuate-tumor-progression-through-induction-of-TPM1-and-PDCD4.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/01/A-pharmaceutical-mixture-encompassing-Mevastatin-or-the-probiotic-Lactobacillus-attenuate-tumor-progression-through-induction-of-TPM1-and-PDCD4.jpg January 19, 2019 January 21, 2019

January 4, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced mutant p53-expressing metastatic cancers: A pharmaceutical mixture encompassing Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as LATS1, SMARCA4, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 4/January/2018, 9.51 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced mutant p53-expressing metastatic cancers: A pharmaceutical mixture encompassing Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as LATS1, SMARCA4, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 4/January/2018, 9.51 am https://genomediscovery.org/wp-content/uploads/2018/12/M-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/M-1.jpg January 4, 2019 January 4, 2019

January 1, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Niclosamide and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as Navigator-3 (Nav3), SMARCA4,p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/January/2018, 6.53 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Niclosamide and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as Navigator-3 (Nav3), SMARCA4,p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/January/2018, 6.53 am https://genomediscovery.org/wp-content/uploads/2018/12/Niclosamide-and-the-probiotic-Lactobacillus-protect-against-cancer-through-induction-of-SMARCA4-and-others.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Niclosamide-and-the-probiotic-Lactobacillus-protect-against-cancer-through-induction-of-SMARCA4-and-others.jpg January 1, 2019 January 1, 2019

Popular Post